Precision BioSciences, Inc. filings document regulatory disclosures for a clinical-stage gene editing company built around the ARCUS platform and in vivo therapeutic candidates. Recent Forms 8-K furnish operating results, financial-condition updates, business presentations, and Regulation FD materials covering PBGENE-HBV in chronic hepatitis B and PBGENE-DMD in Duchenne muscular dystrophy, including IND-related and clinical-development disclosures.
The company’s proxy materials address board and stockholder meeting matters, executive compensation, equity plans, and governance proposals. Other filing categories cover material agreements, shareholder voting matters, capital-structure disclosures, inducement awards, and forward-looking risk language tied to clinical development, financing capacity, regulatory review, and public-company reporting.
Precision BioSciences President and CEO Michael Amoroso reported a mix of RSU vesting and a tax-related share sale. On February 17, 2026, 67,797 Restricted Stock Units vested, with each RSU converting into one share of common stock. On February 18, 2026, he sold 20,559 common shares at $3.84 per share in an open-market transaction executed under a pre-arranged Rule 10b5-1 plan, solely to cover tax withholding and related fees from the RSU vesting. Following these transactions, he directly held 243,392 shares of common stock and 135,593 RSUs, which continue to vest in three substantially equal annual installments beginning February 17, 2026, contingent on continued service.
Precision Biosciences Chief Financial Officer John Alexander reported RSU vesting and related share transactions. On February 17, 2026, 27,584 Restricted Stock Units vested, each representing a right to receive one share of common stock, and were settled into 27,584 common shares at a stated price of $0.00 per share.
On February 18, 2026, he sold 8,149 common shares at $3.84 per share in an open-market transaction executed under a Rule 10b5-1 trading plan. According to the footnotes, this was a sell-to-cover transaction, with shares sold only to satisfy tax withholding and related fees from the RSU vesting.
After these transactions, he directly held 125,883 shares of common stock and 55,166 RSUs, with the RSUs scheduled to vest in three substantially equal annual installments beginning on February 17, 2026, subject to his continued service with the company.
PRECISION BIOSCIENCES INC General Counsel and Secretary Dario Scimeca reported RSU vesting and a related tax sale of common stock. On February 17, 2026, 16,667 Restricted Stock Units vested and converted into 16,667 shares of common stock, increasing his direct holdings. Each RSU represents a right to receive one common share.
On February 18, 2026, he sold 4,925 common shares in an open-market transaction at $3.84 per share under a pre-established Rule 10b5-1 trading plan. The sale was a "sell-to-cover" transaction, with shares sold only to cover tax withholding obligations and related fees from the RSU vesting.
Precision BioSciences Chief Research Officer J. Jefferson Smith reported RSU vesting and a related tax sale of common stock. On February 17, 2026, 16,667 Restricted Stock Units vested, each representing one share of common stock, as part of an award scheduled to vest in three equal annual installments beginning on that date.
In connection with this vesting, on February 18, 2026 he executed an open-market sell-to-cover of 4,925 common shares at $3.84 per share under a pre-established Rule 10b5-1 plan, solely to satisfy tax withholding and related fees. After these transactions, he directly held 121,926 common shares and 33,333 RSUs, with an additional 7,931 common shares held indirectly through a charitable remainder unitrust.
DTIL reported Form 144 transactions involving restricted stock vesting and a recent resale. The filing shows 4,925 common shares listed under "Securities To Be Sold" with an event date of 02/17/2026 described as "Restricted Stock Vesting" and labeled "Issuer" and "Compensation". The filing also records that 10,200 common shares were sold by James Jefferson Revocable Trust on 01/21/2026 for $41,073.36.
DTIL reported an insider sale notice for common stock under Form 144. The filing lists 4,925 shares as restricted stock vesting to be sold on 02/17/2026 and shows 8,854 shares sold during the prior three months on 01/21/2026. The broker listed is Fidelity Brokerage Services LLC.
DTIL reported a Form 144 filing in which Michael Amoroso indicated a sale of 34,799 common shares on 01/22/2026 for $145,202.30. The filing also shows 20,559 common shares vested as restricted stock on 02/17/2026 as compensation.
DTIL insider John A. Kelly filed a Form 144 reporting a proposed sale of 8,149 common shares that vested as restricted stock on 02/17/2026, handled through Fidelity Brokerage Services LLC. The filing also discloses a prior sale of 15,213 common shares on 01/21/2026.
Tang Capital Management and related entities report that they no longer own any Precision BioSciences, Inc. common stock. In Amendment No. 3 to their Schedule 13G, they state beneficial ownership of 0 shares, representing 0% of the company’s common stock as of December 31, 2025.
Each reporting person lists zero sole or shared voting power and zero sole or shared dispositive power over Precision BioSciences shares. They also certify that any securities previously held were not acquired or held to change or influence control of the company.
Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of 993,913 shares of Precision BioSciences, Inc. common stock, equal to 4.1% of the class as of the calculation date. They hold shared voting and dispositive power over all reported shares, with no sole authority.
The ownership percentage is based on 24,071,751 shares of common stock outstanding, combining 10,815,000 shares issued in a recent offering with 13,256,751 shares outstanding as of October 29, 2025. The reporting persons certify the position is not held to change or influence control of the company.